Amazon’s search algorithm gives preferential treatment to books that promote false claims about vaccines, according to research by UW Information School Ph.D. student Prerna Juneja and Assistant Professor Tanu Mitra.
Interim analysis from phase 3 trial of nearly 20,000 participants suggests efficacy of two-dose regimen of the adenovirus-based vaccine is 91.6% against symptomatic COVID-19 - trial reports 16 COVID-19 cases in the vaccine group (0.1% [16/14,964) and 62 cases (1.3% [62/4,902]) in the placebo group.
Using neutron experiments and computer simulations, researchers from Oak Ridge National Laboratory delved into how some of the proposed COVID-19 drug candidates behave at the molecular scale when exposed to water.
The COVID-19 vaccines have been described by many as the light at the end of the tunnel and the best tool we have to stop this pandemic. But along with the vaccine rollout, there have been a number of myths circulating about their safety and effectiveness. To set the record straight, Cedars-Sinai's Newsroom talked with Priya Soni, MD, a pediatrician and an infectious disease specialist.
A $1.2. million challenge grant from the Mabee Foundation brings Texas Biomedical Research Institute (Texas Biomed) closer to its goal of $10 million to fund the construction of its Nonhuman Primate Animal Facility (NHP ALFA) on its campus. The Institute is more than halfway to its goal. This project will accommodate the critical need of the Southwest National Primate Research Center (SNPRC) to provide innovative, contemporary accommodations and laboratory space for animals involved in research that aid in testing the safety and efficacy of new and improved diagnostics, therapies and vaccines at a larger scale.
Kinks in new production and distribution supply chains are why COVID-19 vaccines approved for use in the United States have been sluggish finding their way into people’s arms, says an expert in logistics and supply chains at The University of Alabama in Huntsville (UAH), a part of the University of Alabama System.
A new modelling study has estimated that from 2000 to 2030 vaccination against 10 major pathogens - including measles, rotavirus, HPV and hepatitis B - will have prevented 69 million deaths in low-income and middle-income countries (LMICs).
A remarkable number of pharmaceutical company leaders and chief scientists will come together at a two-day symposium to present efficacy data and updates on twelve vaccines and vaccines candidates. This includes the Moderna and Pfizer mRNA vaccines that have been approved in the US for emergency use. Other topics will include: the clinical epidemiology of COVID-19; the virology, immunology, and genetics of SARS-CoV-2; and research on COVID-19 vaccines in in the elderly.
The AAVCOVID vaccine program, a novel gene-based vaccine strategy that utilizes an adeno-associated virus (AAV) vector, was granted an award for up to $2.1 million from the Bill & Melinda Gates Foundation. In data released in preprint, two AAVCOVID vaccine candidates led to robust neutralizing antibody responses in mouse and nonhuman primate models from only a single dose. The candidates were also shown to be safe and well-tolerated in both models.
People now have access to better real-time information about COVID-19 infection and transmission rates, but they still have to decide what is safe to do. A new model co-authored by mathematician John McCarthy at Washington University in St. Louis helps to contend with the uncertainty.
A new vaccine development platform has proven effective in protecting against deadly, hard-to-treat infections caused by multi-drug resistant (MDR) bacteria, thanks to a collaborative endeavor led by Dr. Michael J. Daly, a professor in the Uniformed Services University's (USU) Department of Pathology, Dr. Gregory J. Tobin, president of Biological Mimetics, Inc., and Dr. Daniel Zurawski at the Walter Reed Army Institute of Research. This could ultimately help prevent battlefield infections, as well as common hospital-acquired infections in patients undergoing routine surgeries.
Uniformed Services University researchers working on a new gamma radiation vaccine development platform have been recognized for their efforts, earning the prestigious 2021 Federal Laboratory Consortium’s (FLC) Award for Technology Transfer.
Among infectious diseases that have caused pandemics and epidemics, smallpox stands out as a success story. Smallpox vaccination led to the disease's eradication in the twentieth century.
Vaccines take time to work. After getting a COVID-19 vaccine, it takes a while for the immune system to fully respond and provide protection from the virus. For the Moderna and Pfizer COVID-19 vaccines, it takes up to two weeks after the second shot to become appropriately protected.
Research from the University of Georgia shows that state laws promoting flu vaccinations for hospital workers can substantially reduce the number of influenza-related deaths.
The testing plan for the "British variant" is based on findings of pre-clinical tests showing stenoparib blocks infection and the replication of SARS-CoV-2, as recently published in peer-reviewed journal mBio.
A Northern California man died on January 21st, several hours after receiving a dose of the COVID-19 vaccine, according to Placer County Public Health and the Placer County Sheriff's Office. It should be said that the man The man previously tested positive for the coronavirus in late December. There is no evidence that the vaccine was the cause of death.
A group of scientists is calling on governments to consider the continued use of strict control measures as the only way to reduce the evolution and spread of new COVID-19 variants.
The University of Miami Health System is one of five sites nationally and the only one in the Southeast U.S. chosen to participate in a National Institute of Allergy and Infectious Diseases (NIAID) study looking at people who have had COVID-19 or have had a COVID-19 vaccine to examine the durability and robustness of participants’ antibody and T-cell responses to the virus.
A Woman’s Journey will host a 90-minute virtual event, “COVID-19: One Year Later,” during which Johns Hopkins Medicine experts will address important issues related to COVID-19 such as new and available treatments and vaccine safety and efficacy. Registrants will learn about the continued urgency of public health measures to mitigate the pandemic despite the introduction of vaccines, what distinguishes the leading vaccine contenders in their methodology, safety and effectiveness, and symptoms and insights surrounding lingering deficits in physical function, mental health and cognition among COVID-19 survivors.
At 30 weeks pregnant, most women would be putting the finishing touches on the nursery, rounding up remaining baby gear, and packing their hospital bag. But Jacqueline Parchem, MD, was faced with an additional task – deciding whether to receive the COVID-19 vaccine despite limited data for pregnant women.
In a promising result for the success of vaccines against COVID-19, rhesus macaque monkeys infected with the human coronavirus SARS-CoV-2 developed protective immune responses that might be reproduced with a vaccine.
The National Comprehensive Cancer Network put out new guidance for COVID-19 vaccinations in people with cancer, based on available evidence plus consensus from top hematology and oncology experts with particular expertise in infectious diseases, vaccine development and delivery, and medical ethics.
This JAMA Insights review provides clinical details of anaphylactic reactions reported to and verified by the Centers for Disease Control and Prevention in the first week of use of the Pfizer-BioNTech COVID-19 vaccine in the United States.
New coronavirus strains — some more contagious than the prevalent strain — continue to be identified across the globe. David Cennimo, a pediatric infectious disease expert and assistant professor at Rutgers New Jersey Medical School, discusses what we know about the new variants and how to stay safe.
Provincial and territorial governments should set clear rules for vaccinating health care workers against SARS-CoV-2, the virus that causes COVID-19, in public and private settings, and should not leave this task to employers, according to an analysis in CMAJ (Canadian Medical Association Journal).
Developed by a research team led by Maurizio Porfiri, Institute Professor at the NYU Tandon School of Engineering, a novel open-source platform comprises an agent-based model (ABM) of COVID-19 for the entire town of New Rochelle, in Westchester County, New York State.
Scientists have shown that two species of seasonal human coronavirus related to SARS-CoV-2 can evolve in certain proteins to escape recognition by the immune system, according to a study published today in eLife.
Cornell University is partnering with New York state and Northwell Health System to develop and train the nation’s first state public health corps, which will support COVID-19 vaccination and improve long-term public health outcomes.
ConserV Bioscience Limited (CBL) and Lawrence Livermore National Laboratory (LLNL) have agreed to collaborate on the development of a broad-spectrum or “universal” coronavirus vaccine.
The Front Line COVID-19 Critical Care Alliance (FLCCC) has issued a public response to the National Institutes of Health (NIH) regarding the NIH COVID-19 Treatment Guidelines Panel’s “neither for nor against” recommendation for the use of ivermectin in the treatment of COVID-19.
If pregnant individuals catch COVID they will generally get sicker than non-pregnant individuals. They also more commonly end up on ECMO [heart-lung support], in the ICU or on ventilators.
Even people who have experienced severe allergic reactions to food, latex, pets, pollen, or bee stings should get the coronavirus vaccine, UW Medicine allergy and infectious disease experts say.
As the vaccination of older adults against COVID-19 begins across the country, new poll data suggests that many of them don’t yet have access to the “patient portal” online systems that could make it much easier for them to schedule a vaccination appointment. In all, 45% of adults aged 65 to 80 had not set up an account with their health provider’s portal system.
Israel's Technion will award an honorary doctorate to Pfizer CEO and Chairman Dr. Albert Bourla, for leading the development of the novel vaccine against SARS-CoV-2, the virus that causes COVID-19. The honorary doctorate will be conferred at the Technion Board of Governors meeting in November 2021.
Researchers at the University of Wisconsin School of Medicine and Public Health and UW Health have developed a tool that incorporates a person’s age and socioeconomic status to prioritize vaccine distribution among people who otherwise share similar risks due to their jobs.
AACI was invited last summer to join the Vaccine Consultation Panel (VCP) alongside other leading health and science organizations in the U.S. Through the VCP, AACI has received periodic updates on the development and distribution of COVID-19 vaccines and participated in efforts to educate the cancer center community and the general public on the importance of widespread vaccine uptake.